MY199335A - Garp-tgf- antibodies - Google Patents

Garp-tgf- antibodies

Info

Publication number
MY199335A
MY199335A MYPI2019006528A MYPI2019006528A MY199335A MY 199335 A MY199335 A MY 199335A MY PI2019006528 A MYPI2019006528 A MY PI2019006528A MY PI2019006528 A MYPI2019006528 A MY PI2019006528A MY 199335 A MY199335 A MY 199335A
Authority
MY
Malaysia
Prior art keywords
antibodies
tgf
antigen binding
garp
binding fragments
Prior art date
Application number
MYPI2019006528A
Other languages
English (en)
Inventor
Haard Johannes De
Der Woning Sebastian Van
Filip Borgions
Torsten Dreier
Boeck Gitte De
Stphanie Lienart
Sophie Lucas
Pierre Coulie
Marin Lore
Federica Linty
Michael Saunders
Original Assignee
argenx BV
Univ Catholique Louvain
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by argenx BV, Univ Catholique Louvain filed Critical argenx BV
Publication of MY199335A publication Critical patent/MY199335A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MYPI2019006528A 2017-05-11 2018-05-11 Garp-tgf- antibodies MY199335A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1707561.5A GB201707561D0 (en) 2017-05-11 2017-05-11 GARP-TGF-beta antibodies
PCT/EP2018/062251 WO2018206790A1 (en) 2017-05-11 2018-05-11 GARP-TGF-β ANTIBODIES

Publications (1)

Publication Number Publication Date
MY199335A true MY199335A (en) 2023-10-24

Family

ID=59201573

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2019006528A MY199335A (en) 2017-05-11 2018-05-11 Garp-tgf- antibodies

Country Status (35)

Country Link
US (4) US10479829B2 (enExample)
EP (3) EP4086286A1 (enExample)
JP (2) JP7118135B2 (enExample)
KR (2) KR102664663B1 (enExample)
CN (1) CN110945027B (enExample)
AU (2) AU2018265241B2 (enExample)
BR (1) BR112019023735A8 (enExample)
CA (1) CA3061841C (enExample)
CL (1) CL2019003211A1 (enExample)
CO (1) CO2019013669A2 (enExample)
CR (1) CR20190561A (enExample)
CY (1) CY1125674T1 (enExample)
DK (1) DK3606961T3 (enExample)
DO (1) DOP2019000285A (enExample)
EC (1) ECSP19087742A (enExample)
ES (1) ES2921015T3 (enExample)
GB (1) GB201707561D0 (enExample)
HR (1) HRP20220787T1 (enExample)
HU (1) HUE059237T2 (enExample)
IL (2) IL305613A (enExample)
LT (1) LT3606961T (enExample)
MX (1) MX385670B (enExample)
MY (1) MY199335A (enExample)
NZ (1) NZ758647A (enExample)
PE (1) PE20200618A1 (enExample)
PH (1) PH12019502526A1 (enExample)
PL (1) PL3606961T3 (enExample)
PT (1) PT3606961T (enExample)
RS (1) RS63361B1 (enExample)
RU (1) RU2767784C2 (enExample)
SG (1) SG10201914130VA (enExample)
SI (1) SI3606961T1 (enExample)
SM (1) SMT202200284T1 (enExample)
UA (1) UA125534C2 (enExample)
WO (1) WO2018206790A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3960855A1 (en) * 2001-12-28 2022-03-02 Chugai Seiyaku Kabushiki Kaisha Method for stabilizing proteins
US11046782B2 (en) * 2016-03-30 2021-06-29 Musc Foundation For Research Development Methods for treatment and diagnosis of cancer by targeting glycoprotein A repetitions predominant (GARP) and for providing effective immunotherapy alone or in combination
KR102376605B1 (ko) 2019-08-28 2022-03-21 추가이 세이야쿠 가부시키가이샤 종교차성 항잠재형 TGF-β1 항체 및 사용 방법
US20240190961A1 (en) 2019-10-25 2024-06-13 Daiichi Sankyo Company, Limited Combination of anti-garp antibody and immunomodulator
MX2022008609A (es) * 2020-01-11 2022-11-10 Scholar Rock Inc Inhibidores de tgf¿ y uso de los mismos.
CN115243724B (zh) 2020-02-19 2025-10-21 纳米医疗有限公司 可用于治疗癌症的经调配和/或共调配的含有TFGβ拮抗剂前药的脂质体组合物和其方法
US20230192867A1 (en) * 2020-05-15 2023-06-22 Bristol-Myers Squibb Company Antibodies to garp
AU2021380681A1 (en) * 2020-11-11 2023-06-15 Versapeutics Inc. Antibody variants against wnt receptor ryk
AU2021391054A1 (en) * 2020-12-02 2023-06-22 Shanghai Henlius Biotech, Inc. ANTI-GARP/TGFβ ANTIBODIES AND METHODS OF USE
BR112023014319A2 (pt) * 2021-01-18 2023-09-26 Jiangxi Jemincare Group Co Ltd Anticorpo contra a proteína garp e aplicação do mesmo
EP4526330A1 (en) 2022-05-18 2025-03-26 Vestaron Corporation Pesticidal actx peptide variants
JP2025526336A (ja) 2022-07-22 2025-08-13 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル Ｔ細胞悪性腫瘍におけるバイオマーカー及びバイオターゲットとしてのｇａｒｐ
CN119630418A (zh) 2022-07-29 2025-03-14 艾伯维生物制药股份有限公司 抗GARP-TGF-β1/PD-1组合疗法
WO2024149237A1 (zh) 2023-01-09 2024-07-18 北京拓界生物医药科技有限公司 TGFβ1结合分子、GARP-TGFβ1结合分子及其医药用途
WO2024164807A1 (zh) * 2023-02-06 2024-08-15 贝达药业股份有限公司 多特异性抗体及其应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5892019A (en) 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
EP0617706B1 (en) 1991-11-25 2001-10-17 Enzon, Inc. Multivalent antigen-binding proteins
NZ298145A (en) 1994-12-29 1998-08-26 Yamanouchi Pharma Co Ltd Monoclonal antibodies having inhibitory effect on type ii phospholipase a2, proteins forming part thereof, cells producing them, dna encoding them, recombinant vector comprising the dna and medicament
US7709610B2 (en) 2003-05-08 2010-05-04 Facet Biotech Corporation Therapeutic use of anti-CS1 antibodies
ES2304069B1 (es) * 2003-08-22 2009-08-12 Proyecto De Biomedicina Cima, S.L. Peptidos con capacidad de unirse al factor transformante de crecimiento beta 1 (tgf-b1).
US20070048785A1 (en) 2004-06-09 2007-03-01 Lin Laura L Anti-IL-13 antibodies and complexes
US8815526B2 (en) 2005-03-31 2014-08-26 Case Western Reserve University Methods and reagents for identifying/isolating T regulatory (Treg) cells and for treating individuals
US20110086367A1 (en) 2006-04-03 2011-04-14 Medizinische Hochschule Hannover Pharmaceuticals for influencing the reaction of the human immune system
WO2009073163A1 (en) 2007-12-03 2009-06-11 American Type Culture Collection (Atcc) Avian influenza antibodies, compositions, and methods thereof
GB2461546B (en) 2008-07-02 2010-07-07 Argen X Bv Antigen binding polypeptides
WO2010022341A1 (en) 2008-08-21 2010-02-25 The United State Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of enriching and using regulatory t cells
KR101492052B1 (ko) 2012-06-26 2015-02-10 (주)대창솔루션 액화가스 운반용 탱크
EP2890711B1 (en) 2012-08-31 2017-01-04 Argen-X Nv Method for producing antibody molecules having inter-species, intra-target cross-reactivity
AU2014262843B2 (en) 2013-05-06 2017-06-22 Scholar Rock, Inc. Compositions and methods for growth factor modulation
EP2832747A1 (en) * 2013-08-01 2015-02-04 Université Catholique de Louvain Anti-GARP protein and uses thereof
SG10201800889SA (en) * 2013-08-01 2018-03-28 Univ Catholique Louvain Anti-garp protein and uses thereof
EP3253796A1 (en) 2015-02-03 2017-12-13 Université Catholique de Louvain Anti-garp protein and uses thereof
AU2016325858B2 (en) 2015-09-24 2022-05-26 Daiichi Sankyo Company, Limited Anti-GARP antibody
SG11201900200XA (en) * 2016-07-14 2019-02-27 Scholar Rock Inc Tgfb antibodies, methods, and uses

Also Published As

Publication number Publication date
EP3606961B1 (en) 2022-06-01
CR20190561A (es) 2020-04-04
DK3606961T3 (da) 2022-07-04
RU2767784C2 (ru) 2022-03-21
KR102664663B1 (ko) 2024-05-23
HUE059237T2 (hu) 2022-11-28
CN110945027B (zh) 2023-08-01
EP3606961A1 (en) 2020-02-12
EP4282430A3 (en) 2024-04-03
IL270236B1 (en) 2023-10-01
CO2019013669A2 (es) 2020-04-01
US20190375832A1 (en) 2019-12-12
AU2018265241B2 (en) 2021-11-04
CY1125674T1 (el) 2025-05-09
EP4086286A1 (en) 2022-11-09
US20180327487A1 (en) 2018-11-15
UA125534C2 (uk) 2022-04-13
EP3606961B8 (en) 2022-07-13
MX385670B (es) 2025-03-18
PT3606961T (pt) 2022-07-04
PL3606961T3 (pl) 2022-08-16
IL270236A (enExample) 2019-12-31
PH12019502526A1 (en) 2020-07-20
US20210324061A1 (en) 2021-10-21
CA3061841C (en) 2022-08-09
KR20200027469A (ko) 2020-03-12
SMT202200284T1 (it) 2022-09-14
DOP2019000285A (es) 2020-07-15
BR112019023735A8 (pt) 2023-01-31
SG10201914130VA (en) 2020-03-30
US10875914B2 (en) 2020-12-29
US10793627B2 (en) 2020-10-06
US10479829B2 (en) 2019-11-19
IL270236B2 (en) 2024-02-01
JP7118135B2 (ja) 2022-08-15
JP2020519308A (ja) 2020-07-02
BR112019023735A2 (pt) 2020-06-09
AU2021240255A1 (en) 2021-10-28
WO2018206790A1 (en) 2018-11-15
AU2018265241A1 (en) 2019-11-21
LT3606961T (lt) 2022-07-11
RS63361B1 (sr) 2022-07-29
CN110945027A (zh) 2020-03-31
JP2022169549A (ja) 2022-11-09
SI3606961T1 (sl) 2022-10-28
US20200095311A1 (en) 2020-03-26
ECSP19087742A (es) 2020-05-29
RU2019140602A (ru) 2021-06-11
HRP20220787T1 (hr) 2022-09-16
KR20240065192A (ko) 2024-05-14
IL305613A (en) 2023-11-01
CA3061841A1 (en) 2018-11-15
NZ758647A (en) 2022-07-29
MX2019013490A (es) 2021-08-26
ES2921015T3 (es) 2022-08-16
EP4282430A2 (en) 2023-11-29
RU2019140602A3 (enExample) 2021-07-23
GB201707561D0 (en) 2017-06-28
CL2019003211A1 (es) 2020-04-24
PE20200618A1 (es) 2020-03-11

Similar Documents

Publication Publication Date Title
MY199335A (en) Garp-tgf- antibodies
MX2022004072A (es) Anticuerpos de factor xi y metodos de uso.
MY191649A (en) Antibodies to tigit
MY205789A (en) Anti-gdf15 antibodies, compositions and methods of use
EP4417263A3 (en) Cd3 binding antibodies
PH12018502225A1 (en) Anti-il-33 antibodies, compositions, methods and uses thereof
HK1258444A1 (zh) 抗wt1/hla特异性抗体
MX2018010948A (es) INMUNOGLOBULINAS DE ENLACE A TGFß1 Y USOS DE LAS MISMAS.
GEP20217220B (en) Pd1 and/or lag3 binders
NZ739499A (en) Single domain antibody for programmed death-ligand (pd-l1) and derived protein thereof
SG10201909716RA (en) Modified j-chain
WO2015112886A3 (en) Binding proteins and methods of use thereof
MX2024003743A (es) Inmunoglobulinas de union a agrecano.
WO2017015622A8 (en) Gdf11 binding proteins and uses thereof
MX2018000470A (es) Moleculas de anticuerpo que se unen al grupo de diferenciacion 22 (cd22).
WO2017106684A3 (en) Antibodies specifically binding hla-dr and their uses
WO2017019957A3 (en) Binding proteins and methods of use thereof
WO2016016651A3 (en) Pfrh5 derived antigen for treatment of malaria
WO2019094533A8 (en) Angptl8-binding agents and methods of use thereof
MX2019009498A (es) Anticuerpos mimeticos de fgf21 y usos de los mismos.
GB2568440A (en) Modified factor H binding protein
MX2022005718A (es) Anticuerpos tmem219 y usos terapeuticos de los mismos.
WO2018227063A8 (en) Anti-robo2 antibodies, compositions, methods and uses thereof
WO2017089780A3 (en) Peptides
WO2017075484A3 (en) Highly potent antibodies binding to death receptor 4 and death receptor 5